Eyyüp KARAHAN, Sülen SARIOĞLU, Hakan YILDIRIM, Gönen BAŞER, Oya Nermin SİVRİKOZ, Emine ŞEKER ÜN

Chemokine CXCR-4 and cyclooxygenase-2 in the pathogenesis of pterygium

Background/aim: This study aimed to investigate the expression of chemokine receptor 4 (CXCR-4) and cyclooxygenase-2 (COX-2) in the epithelium and stroma of pterygium tissue in comparison with healthy conjunctiva. Materials and methods: The expression of CXCR4 and COX-2 was investigated by immunohistochemistry in the epithelium and stroma of the pterygium tissue of 29 eyes and compared with healthy conjunctival tissues. The correlation between CXCR4 and COX-2 expression as well as the correlation of these markers with the area of pterygium were evaluated statistically. Results: COX-2 staining scores were 1.75 ± 0.63 in the epithelium and 1.20 ± 0.62 in the stroma of the pterygium tissue. Mean CXCR-4 staining in the epithelium was 0.069 ± 0.37, whereas it was 5.0 ± 2.84 cells in the stroma. There was almost no staining of COX-2 and CXCR4 in the control samples. There was a strong positive correlation between the expression of CXCR-4 and COX-2 in the stroma of the pterygium. Conclusion: CXCR-4 and COX-2 may play important roles in the pathogenesis of pterygium.

PDF

___

1. Coroneo MT, Giralomo N, Wakefield D. The pathogenesis of pterygia. Curr Opin Ophthalmol 2009; 10: 282-288.
2. Karagece YU, Seckin S. The expression of p53 and COX-2 in basal cell carcinoma, squamous cell carcinoma and actinic keratosis cases. Turkish Journal of Pathology 2012; 28: 119- 127.
3. Tsai YY, Chang CC, Chiang CC, Yeh KT, Chen PL, Chang CH, Chou MC, Lee H, Cheng YW. HPV infection and p53 inactivation in pterygium. Mol Vis 2009; 15: 1092-1097.
4. Hirst LW, Axelsen RA, Schwab I. Pterygium and associated ocular surface squamous neoplasia. Arch Ophthalmol 2009; 127: 31-32.
5. Chui J, Coroneo MT, Tat LT, Crouch R, Wakefield D, Di Girolamo N. Ophthalmic pterygium: a stem cell disorder with premalignant features. Am J Pathol 2011; 178: 817-827.
6. Chen GS, Yu HS, Lan CC, Chow KC, Lin TY, Kok LF, Lu MP, Liu CH, Wu MT. CXC chemokine receptor CXCR4 expression enhances tumorigenesis and angiogenesis of basal cell carcinoma. Br J Dermatol 2006; 154: 910-918.
7. Chu CY, Cha ST, Lin WC, Lu PH, Tan CT, Chang CC, Lin BR, Jee SH, Kuo ML. Stromal cell-derived factor-1α (SDF1α/ CXCL12)-enhanced angiogenesis of human basal cell carcinoma cells involves ERK1/2-NF-κB/interleukin-6 pathway. Carcinogenesis 2009; 30: 205-213.
8. Wald O, Shapira OM, Izhar U. CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential. Theranostics 2013; 3: 26-33.
9. Mukherjee D, Zhao J. The role of chemokine receptor CXCR4 in breast cancer metastasis. Am J Cancer Res 2013; 3: 46-55.
10. Toyozawa S, Kaminaka C, Furukawa F, Nakamura Y, Matsunaka H, Yamamoto Y. Chemokine receptor CXCR4 is a novel marker for the progression of cutaneous malignant melanomas. Acta Histochem Cytochem 2012; 45: 293-299.
11. Sciaccaluga M, DAlessandro G, Pagani F, Ferrara G, Lopez N, Warr T, Gorello P, Porzia A, Mainiero F, Santoro A et al. Functional cross talk between CXCR4 and PDGFR on glioblastoma cells is essential for migration. PLoS One 2013; 8: e73426.
12. Ohira S, Sasaki M, Harada K, Sato Y, Zen Y, Isse K, Kozaka K, Ishikawa A, Oda K, Nimura Y et al. Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma. Am J Pathol 2006; 168: 1155-1168.
13. Shirahama T, Sakakura C. Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder. Clin Cancer Res 2001; 7: 558-561.
14. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 2000; 30: 3-21.
15. Zhan H, Zheng H. The role of topical cyclo-oxygenase-2 inhibitors in skin cancer: treatment and prevention. Am J Clin Dermatol 2007; 8: 195-200.
16. Rao SK, Lekha T, Mukesh BN, Sitalakshmi G, Padmanabhan P. Conjunctival-limbal autografts for primary and recurrent pterygia: technique and results. Indian J Ophthalmol 1998; 46: 203-209.
17. Kim KW, Park SH, Lee SH, Kim JC. Upregulated stromal cellderived factor 1 (SDF-1) expression and its interaction with CXCR4 contribute to the pathogenesis of severe pterygia. Invest Ophthalmol Vis Sci 2013; 54: 7198-7206.
18. Sivrikoz ON, Uyar B, Dag F, Taşlı F, Sanal SM. CXCR-4 and COX-2 expression in basal cell carcinomas and welldifferentiated squamous cell carcinomas of the skin; their relationship with tumor invasiveness and histological subtype. Turkish Journal of Pathology 2014; 31: 30-35.
19. Park CY, Choi JS, Lee SJ, Hwang SW, Kim EJ, Chuck RS. Cyclooxygenase-2-expressing macrophages in human pterygium co-express vascular endothelial growth factor. Mol Vis 2011; 17: 3468-3480.
20. Todani A, Melki SA. Pterygium: current concepts in pathogenesis and treatment. Int Ophthalmol Clin 2009; 49: 21- 30.
21. Seet LF, Tong L, Su R, Wong TT. Involvement of SPARC and MMP-3 in the pathogenesis of human pterygium. Invest Ophthalmol Vis Sci. 2012; 53: 587-595.
22. Poenaru Sava MG, Raica ML, Cimpean AM. VEGF mRNA assessment in human pterygium: a new scope for a future hope. Ophthalmic Res 2014; 52: 130-135.
23. Lee K, Young Lee S, Park SY, Yang H. Antifibrotic effect of pirfenidone on human pterygium fibroblasts. Curr Eye Res 2014; 39: 680-685.
24. Chiang CC, Cheng YW, Lin CL, Chiang CC, Cheng YW, Lin CL, Lee H, Tsai FJ, Tseng SH, Tsai YY. Cyclooxygenase 2 expression in pterygium. Mol Vis 2007; 13: 635-638.
25. Adiguzel U, Karabacak T, Sari A, Oz O, Cinel L. Cyclooxygenase-2 expression in primary and recurrent pterygium. Eur J Ophthalmol 2007; 17: 879-884.
26. Karahan N, Baspinar S, Ciris M, Baydar CL, Kapucuoglu N. Cyclooxygenase-2 expression in primary and recurrent pterygium. Indian J Ophthalmol 2008; 56: 279-283.
27. Maxia C, Perra MT, Demurtas P, Minerba L, Murtas D, Piras F, Cabrera R, Ribatti D, Sirigu P. Relationship between the expression of cyclooxygenase-2 and survivin in primary pterygium. Mol Vis 2009; 15: 458-463.
28. Zhan H, Zheng H. The role of topical cyclo-oxygenase-2 inhibitors in skin cancer: Treatment and prevention. Am J Clin Dermatol 2007; 8: 195-200.
29. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 2003; 200: 500-503.
30. Touhami A, Di Pascuale MA, Kawatika T, Del Valle M, Rosa RH Jr, Dubovy S, Tseng SC. Characterisation of myofibroblasts in fibrovascular tissues of primary and recurrent pterygia. Br J Ophthalmol 2005; 89: 269-274.
31. Di Girolamo N. Signalling pathways activated by ultraviolet radiation: role in ocular and cutaneous health. Curr Pharm Des 2010; 16: 1358-1375.
32. Di Girolamo N, Wakefield D, Coroneo MT. UVB-mediated induction of cytokines and growth factors in pterygium epithelial cells involves cell surface receptors and intracellular signaling. Invest Ophthalmol Vis Sci 2006; 47: 2430-2437.
33. Katoh H, Hosono K, Ito Y, Suzuki T, Ogawa Y, Kubo H, Kamata H, Mishima T, Tamaki H, Sakagami H et al. COX-2 and prostaglandin EP3/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems. Am J Pathol 2010; 176: 1469-1483.
34. Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinsk. PGE2 -induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res 2011; 71: 7463-7470.
35. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 1989, 2: 98-101.